DILAUDID Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Dilaudid, and what generic alternatives are available?
Dilaudid is a drug marketed by Fresenius Kabi Usa and Rhodes Pharms and is included in three NDAs. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has twenty-two patent family members in twelve countries.
The generic ingredient in DILAUDID is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dilaudid
A generic version of DILAUDID was approved as hydromorphone hydrochloride by HIKMA on July 29th, 1998.
Summary for DILAUDID
International Patents: | 22 |
US Patents: | 2 |
Applicants: | 2 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Clinical Trials: | 102 |
Patent Applications: | 3,559 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for DILAUDID |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DILAUDID |
What excipients (inactive ingredients) are in DILAUDID? | DILAUDID excipients list |
DailyMed Link: | DILAUDID at DailyMed |



Recent Clinical Trials for DILAUDID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Miami | Phase 2 |
The Cleveland Clinic | N/A |
Hennepin Healthcare Research Institute | Phase 4 |
Pharmacology for DILAUDID
Drug Class | Opioid Agonist |
Mechanism of Action | Full Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for DILAUDID
Paragraph IV (Patent) Challenges for DILAUDID
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DILAUDID | Tablets | hydromorphone hydrochloride | 2 mg, 4 mg, and 8 mg | 019892 | 1 | 2013-08-05 |
DILAUDID | Oral Solution | hydromorphone hydrochloride | 5 mg/5mL | 019891 | 1 | 2011-02-25 |
US Patents and Regulatory Information for DILAUDID
DILAUDID is protected by two US patents.
Patents protecting DILAUDID
Packaging system for oxygen-sensitive drugs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Drug container
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Expired US Patents for DILAUDID
International Patents for DILAUDID
See the table below for patents covering DILAUDID around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2338891 | ⤷ Try a Trial | |
Japan | 2012510330 | ⤷ Try a Trial | |
European Patent Office | 2968729 | SYSTÈME D'EMBALLAGE POUR MÉDICAMENTS SENSIBLES À L'OXYGÈNE (PACKAGING SYSTEM FOR OXYGEN-SENSITIVE DRUGS) | ⤷ Try a Trial |
Spain | 2693123 | ⤷ Try a Trial | |
European Patent Office | 2376147 | RÉCIPIENT DE MÉDICAMENT AMÉLIORÉ (IMPROVED DRUG CONTAINER) | ⤷ Try a Trial |
Japan | 4886953 | ⤷ Try a Trial | |
China | 204798475 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |